<?xml version="1.0" encoding="utf-8"?>
<NewsML Version="1.2"><!--AFP NewsML text-photo profile evolution2--><!--Processed by Xafp1-4ToNewsML1-2 rev31--><Catalog Href="http://www.afp.com/dtd/AFPCatalog.xml"/>
<NewsEnvelope><TransmissionId>0655</TransmissionId><SentTo><Party FormalName="Business Wire"/></SentTo><DateAndTime>20231121T120000Z</DateAndTime><NewsService FormalName="DGTE"/><NewsProduct FormalName="BWEA"/><NewsProduct FormalName="BWEU"/><Priority FormalName="4"/></NewsEnvelope><NewsItem xml:lang="en"><Identification><NewsIdentifier><ProviderId>afp.com</ProviderId><DateId>20231121T120015Z</DateId><NewsItemId>TX-PAR-ETN60</NewsItemId><RevisionId PreviousRevision="0" Update="N">1</RevisionId><PublicIdentifier>urn:newsml:afp.com:20231121T120015Z:TX-PAR-ETN60:1</PublicIdentifier></NewsIdentifier><NameLabel>Research-Technology-Health-Technology-Software-Biotechnology</NameLabel></Identification><NewsManagement><NewsItemType FormalName="News"/><FirstCreated>20231121T120015+0000</FirstCreated><ThisRevisionCreated>20231121T120015+0000</ThisRevisionCreated><Status FormalName="Usable"/><Urgency FormalName="4"/><AssociatedWith NewsItem="urn:newsml:businesswire.com:20010714:20231121531974"/></NewsManagement><NewsComponent><NewsLines><DateLine xml:lang="en">OXFORD, Nov 21, 2023 (BSW) -</DateLine><HeadLine xml:lang="en">Press Release from Business Wire: Exscientia plc</HeadLine><SubHeadLine xml:lang="en">Exscientia to Present at the 6th Annual Evercore ISI HealthCONx Conference</SubHeadLine></NewsLines><AdministrativeMetadata><Provider><Party FormalName="BSW"/></Provider><Creator><Party FormalName="JS"><Property FormalName="Role" Value="CaptionWriter"/></Party></Creator></AdministrativeMetadata><DescriptiveMetadata><Language FormalName="en"/><Genre FormalName="PressRelease"/><SubjectCode><SubjectMatter FormalName="04016000" cat="ECO"/></SubjectCode><SubjectCode><Subject FormalName="04000000" cat="ECO"/></SubjectCode><DateLineDate>20231121T120015+0000</DateLineDate><Location HowPresent="Origin"><Property FormalName="City" Value="OXFORD"/></Location><Property FormalName="GeneratorSoftware" Value="ToNewsMLG2"/><Property FormalName="Keyword" Value="Research"/><Property FormalName="Keyword" Value="Technology"/><Property FormalName="Keyword" Value="Health Technology"/><Property FormalName="Keyword" Value="Software"/><Property FormalName="Keyword" Value="Biotechnology"/><Property FormalName="Keyword" Value="Pharmaceutical"/><Property FormalName="Keyword" Value="Health"/><Property FormalName="Keyword" Value="Science"/><Property FormalName="Keyword" Value="Oncology"/><Property FormalName="Keyword" Value="Artificial Intelligence"/><Property FormalName="Keyword" Value="United Kingdom"/><Property FormalName="Keyword" Value="Europe"/></DescriptiveMetadata><ContentItem><MediaType FormalName="Text"/><Format FormalName="NITF3.1"/><Characteristics><SizeInBytes>1428</SizeInBytes><Property FormalName="Words" Value="238"/></Characteristics><DataContent><nitf><body><body.content><p>   
Exscientia plc (Nasdaq: EXAI) today announced that members of Exscientia management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 3:25 p.m. EST (8:25 p.m. GMT).

</p><p>   
A live webcast of the fireside chat will be available on the Company's website, under the "Investors &amp; Media" section at investors.exscientia.ai. An archived replay of the webcast will be available for approximately 30 days following the presentation.

</p><p>   About Exscientia

</p><p>   
Exscientia is an AI-driven precision medicine company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.

</p><p>   
Visit us at www.exscientia.ai or follow us on X/Twitter @exscientiaAI.

</p><p>   
              </p><p>   View source version on businesswire.com: https://www.businesswire.com/news/home/20231121531974/en/
                
              </p><p>   </p><p>   Contact</p><p>   Investor Relations: Sara Sherman
 investors@exscientia.ai

</p><p>   Media: Oliver Stohlmann
 media@exscientia.ai

</p><p>   
© 2023 Business Wire, Inc.

Disclaimer:
This press release is not a document produced by AFP. AFP shall not bear responsibility for its content. In case you have any questions about this press release, please refer to the contact person/entity mentioned in the text of the press release.</p><p><org idsrc="isin" value="US30223G1022"/></p><p/></body.content></body></nitf></DataContent></ContentItem></NewsComponent></NewsItem></NewsML>

